On January 23, 2024, Accent Therapeutics, Inc. closed the transaction. The company issued 90,361,446 shares for gross proceeds of $75,000,000 in the transaction led by new investor, Mirae Assest Capital Life Science. The transaction included participation from new investors, Mirae Asset Capital Co., Ltd., Mirae Asset Venture Investment Co., Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Innovation - JJDC, Inc., returning investors, The Column Group, LLC, Atlas Venture L.P., DROIA nv, GV Management Company, LLC, EcoR1 Capital, LLC, AbbVie Ventures, Inc., The Mark Foundation For Cancer Research, Endowment Arm, NS Investment Co., Ltd. and others.

Naveen Krishnan of Mirae Assest Capital Life Science joins the company's board of directors.